Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: Results from an international surveillance study

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue SUPPL. 4, 2010, Pages

  Jones, Ronald N ^a,b   Mendes, Rodrigo E ^a   Sader, Helio S ^a  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ceftaroline fosamil; cSSSIs; Europe; MRSA; USA

Indexed keywords

AMIKACIN; AMPICILLIN; CEFAZOLIN; CEFEPIME; CEFTAROLINE; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL SKIN DISEASE; BETA HEMOLYTIC STREPTOCOCCUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG POTENCY; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PROTEUS MIRABILIS; SOFT TISSUE INFECTION;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CLINICAL TRIALS, PHASE III AS TOPIC; EUROPE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE COCCI; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TREATMENT OUTCOME; UNITED STATES;

EID: 78649453268     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq252     Document Type: Article

References (44)

1. Iizawa Y, Nagai J, Ishikawa T et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother 2004; 10: 146-56.
2. Ikeda Y, Ban J, Ishikawa T et al. Stability and stabilization studies of TAK-599 (ceftaroline fosamil), a novel N-phosphono type prodrug of anti-methicillin resistant Staphylococcus aureus cephalosporin T-91825. Chem Pharm Bull 2008; 56: 1406-11.
3. Ishikawa T, Matsunaga N, Tawada H et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 2003; 11: 2427-37.
4. Jones RN, Fritsche TR, Ge Y et al. Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J Antimicrob Chemother 2005; 56: 1047-52.
5. Kanafani ZA, Corey GR. Ceftaroline: a cephalosporin with expanded Gram-positive activity. Future Microbiol 2009; 4: 25-33.
6. Sader HS, Fritsche TR, Jones RN. Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52: 1153-5.
7. Sader HS, Fritsche TR, Kaniga K et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005; 49: 3501-12.
8. Zhanel GG, Sniezek G, Schweizer F et al. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs 2009; 69: 809-31.
9. Mushtaq S, Warner M, Ge Y et al. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007; 60: 300-11.
10. Fenoll A, Aguilar L, Robledo O et al. In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime. Antimicrob Agents Chemother 2008; 52: 4209-10.
11. Ge Y, Biek D, Talbot GH et al. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008; 52: 3398-407.
12. McGee L, Biek D, Ge Y et al. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2009; 53: 552-6.
13. Morrissey I, Ge Y, Janes R. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia. Int J Antimicrob Agents 2009; 33: 515-9.
14. Jacqueline C, Caillon J, Le Mabecque V et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 2007; 51: 3397-400.
15. Vidaillac C, Leonard SN, Rybak MJ. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob Agents Chemother 2009; 53: 4712-7.
16. Talbot GH, Thye D, Das A et al. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007; 51: 3612-6.
17. Corey R, Wilcox M, Talbot GH. CANVAS-1: randomized, double-blinded phase 3 study (P903-06) of the efficacy and safety of ceftaroline vs vancomycin plus aztreonam in complicated skin and skin structure infections (cSSSI). In: Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2008. Abstract L-1515a. American Society for Microbiology, Washington, DC, USA.
18. Wilcox M, Corey R, Talbot GH et al. CANVAS-2: randomized, double-blinded phase 3 study (P903-07) of the efficacy and safety of ceftaroline vs vancomycin plus aztreonam in complicated skin and skin structure infections (cSSSI). In: Abstracts of the Nineteenth European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, Finland, 2009. Abstract P-1792. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
19. Eckburg P, Friedland HD, Lee J et al. FOCUS 1 and 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline (CPT) vs ceftriaxone (CRO) in community-acquired pneumonia (CAP). In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract L1-345a. American Society for Microbiology, Washington, DC, USA.
20. Edelsberg J, Taneja C, Zervos M et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis 2009; 15: 1516-8.
21. Tenover FC, Goering RV. Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology. J Antimicrob Chemother 2009; 64: 441-6.
22. Patel SN, Pillai DR, Pong-Porter S et al. In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008. J Antimicrob Chemother 2009; 64: 659-60.
23. Stevens DL. Antimicrobial agents for complicated skin and skinstructure infections: noninferiority margins, placebo-controlled trials, and the complexity of clinical trials. Clin Infect Dis 2009; 49: 392-4.
24. Spellberg B, Talbot GH, Boucher HW et al. Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials. Clin Infect Dis 2009; 49: 383-91.
25. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Ninth Edition: Approved Standard M07-A8. CLSI, Wayne, PA, USA, 2009.
26. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement M100-S19. CLSI, Wayne, PA, USA, 2009.
27. Tygacil (Tigecycline) Prescribing Information. Philadelphia: Wyeth Pharmaceuticals, Inc., 2009.
28. Andes D, Craig WA. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 2006; 50: 1376-83.
29. Brown SD, Traczewski MM. In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob Agents Chemother 2009; 53: 1271-4.
30. Ender M, McCallum N, Berger-Bächi B. Impact of mecA promoter mutations on mecA expression and b-lactam resistance levels. Int J Med Microbiol 2008; 298: 607-17.
31. Enright MC, Day NP, Davies CE et al. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol 2000; 38: 1008-15.
32. Katayama Y, Zhang HZ, Chambers HF. PBP 2a mutations producing very-high-level resistance to b-lactams. Antimicrob Agents Chemother 2004; 48: 453-9.
33. Lina G, Piémont Y, Godail-Gamot F et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29: 1128-32.
34. McDougal LK, Steward CD, Killgore GE et al. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 2003; 41: 5113-20.
35. Milheiriço C, Oliveira DC, de Lencastre H. Update to the multiplex PCR strategy for assignment of mec element types in Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 3374-7.
36. Shopsin B, Gomez M, Montgomery SO et al. Evaluation of protein A gene polymorphic region DNA sequencing for typing of Staphylococcus aureus strains. J Clin Microbiol 1999; 37: 3556-63.
37. Weller TM. The distribution of mecA, mecR1 and mecI and sequence analysis of mecI and the mec promoter region in staphylococci expressing resistance to methicillin. J Antimicrob Chemother 1999; 43: 15-22.
38. Bush K, Heep M, Macielag MJ et al. Anti-MRSA β-lactams in development, with a focus on ceftobiprole: the first anti-MRSA b-lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs 2007; 16: 419-29.
39. Jones RN, Deshpande LM, Mutnick AH et al. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother 2002; 50: 915-32.
40. Llarrull LI, Fisher JF, Mobashery S. Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new b-lactams that meet the challenge. Antimicrob Agents Chemother 2009; 53: 4051-63.
41. Pankuch GA, Appelbaum PC. Postantibiotic effect of ceftaroline against gram-positive organisms. Antimicrob Agents Chemother 2009; 53: 4537-9.
42. Vidaillac C, Leonard SN, Sader HS et al. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53: 2360-6.
43. Corey GR, Wilcox MH, Talbot GH et al. on behalf of the CANVAS 1 investigators. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 Suppl 4: iv41-51.
44. Wilcox MH, Corey GR, Talbot GH et al. on behalf of the CANVAS 2 investigators. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 Suppl 4: iv53-65.